NCT00417222

Supplemental Benefit of Angiotensin Receptor Blocker in Hypertensive Patients With Stable Heart Failure Using Olmesartan

Supplemental Benefit of Angiotensin II Receptor Blocker in Hypertensive Patients With Stable Heart Failure Using Olmesartan (SUPPORT Trial)

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,145 (actual)
• Sponsor: Tohoku University · Academic / Other
• Sex: All
• Age: 20 Years – 79 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to investigate whether an angiotensin II receptor blocker (olmesartan), in addition to conventional treatment, will reduce the mortality and morbidity in hypertensive patients with stable chronic heart failure.

Conditions

• Chronic Heart Failure

Interventions

Type	Name	Description
DRUG	olmesartan medoxomil	5 to 40mg P.O. daily until the end of the study

Timeline

• Start date: 2006-11-01
• Primary completion: 2013-03-01
• Completion: 2013-12-01
• First posted: 2006-12-29
• Last updated: 2014-05-19

Locations

1 site across 1 country: Japan